{"id":"NCT01265667","sponsor":"Can-Fite BioPharma","briefTitle":"Trial of CF101 to Treat Patients With Psoriasis","officialTitle":"A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-07","primaryCompletion":"2015-03","completion":"2015-05","firstPosted":"2010-12-23","resultsPosted":"2017-09-20","lastUpdate":"2020-11-18"},"enrollment":293,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"CF101","otherNames":["IB-MECA"]},{"type":"DRUG","name":"Placebo","otherNames":["Dummy pills"]}],"arms":[{"label":"CF101 2 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.","primaryOutcome":{"measure":"Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks","timeFrame":"12 weeks","effectByArm":[{"arm":"CF101 2 mg","deltaMin":12,"sd":null},{"arm":"Placebo","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":10},"locations":{"siteCount":18,"countries":["United States","Bulgaria","Israel","Romania"]},"refs":{"pmids":[],"seeAlso":["http://www.canfite.com/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":145},"commonTop":["Urinary tract infection","Nasopharyngitis","Diarrhoea","Headache","Haematuria"]}}